Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 29;11(5):921.
doi: 10.3390/vaccines11050921.

Associated Factors and Immune Response to the Hepatitis B Vaccine with a Standard Schedule: A Prospective Study of People with HIV in China

Li Nie  1 , Wei Hua  2 , Xiuying Liu  1 , Xinghuo Pang  1 , Caiping Guo  2 , Wei Zhang  1 , Yakun Tian  2 , Qian Qiu  1
Affiliations

Associated Factors and Immune Response to the Hepatitis B Vaccine with a Standard Schedule: A Prospective Study of People with HIV in China

Li Nie et al. Vaccines (Basel). .

Abstract

Hepatitis B (HB) vaccination is recommended for people with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS). We aimed to assess the immune response to the HB vaccine and associated factors using the standard vaccination schedule among people with HIV (PWH) in China. A prospective study was carried out from 2016 to 2020 in Beijing, China. PWH were given three 20 μg doses of recombinant HB vaccine at 0, 1, and 6 months. Blood samples were taken within 4-6 weeks after each dose to evaluate the anti-HBs levels. A total of 312 participants completed vaccination and serologic testing. The seroconversion (anti-HBs ≥ 10 IU/L) rates following the first, second, and third doses of the vaccine were 35.6% (95% CI: 30.3-40.9%), 55.1% (95% CI: 49.6-60.7%), and 86.5% (95% CI: 82.8-90.3%), respectively, and the geometric means of the anti-HBs titers were 0.8 IU/L (95% CI: 0.5-1.6 IU/L), 15.7 IU/L (95% CI: 9.4-26.3 IU/L), and 241.0 IU/L (95% CI: 170.3-341.1 IU/L), respectively. In multivariate analysis, after three doses of vaccination, age, CD4 cell count, and HIV-RNA viral load were significantly associated with strong, moderate, and weak response, respectively. These findings confirm that these personal health conditions are related to the HB response. HB vaccination in PWH using the standard schedule was still highly effective in the context of early treatment initiation, especially among participants aged 30 years and younger.

Keywords: China; HIV/AIDS; associated factors; hepatitis B vaccine; immune response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the study population.
Figure 2
Figure 2
Percentage of respondents and geometric mean titers (GMTs) of anti-HBs following hepatitis B vaccination (N = 312). The error bars show the 95% confidence intervals (CIs).
Figure 3
Figure 3
Percentage of four levels of response following hepatitis B vaccination (N = 312).
Figure 4
Figure 4
Age-specific percentages of respondents to the hepatitis B vaccine in HIV-infected adults.
Figure 5
Figure 5
Geometric mean titers (GMTs) of anti-HBs following hepatitis B vaccination in different groups in month 7. Error bars show the 95% confidence intervals (CIs).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chen S., Li J., Wang D., Fung H., Wong L.Y., Zhao L. The hepatitis B epidemic in China should receive more attention. Lancet. 2018;391:1572. doi: 10.1016/S0140-6736(18)30499-9. - DOI - PubMed
    1. For a hepatitis-free future. Lancet Reg. Health West. Pac. 2021;12:100234. doi: 10.1016/j.lanwpc.2021.100234. - DOI - PMC - PubMed
    1. Huang S.M., Cai W.P., Hu F.Y., Lan Y., Liao B.L., Chen Y.P., Tang X.P. Epidemiological and clinical characteristics of hepatitis B virus in HIV-infected patients in Guangdong, China. Int. J. STD AIDS. 2016;27:890–897. doi: 10.1177/0956462415600570. - DOI - PubMed
    1. Chen X., He J.M., Ding L.S., Zhang G.Q., Zou X.B., Zheng J. Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China. Arch. Virol. 2013;158:1889–1894. doi: 10.1007/s00705-013-1681-z. - DOI - PubMed
    1. Wu S., Yan P., Yang T., Wang Z., Yan Y. Epidemiological profile and risk factors of HIV and HBV/HCV co-infection in Fujian Province, southeastern China. J. Med. Virol. 2017;89:443–449. doi: 10.1002/jmv.24666. - DOI - PubMed